| Autor: |
Agha R; Department of Dermatology, University of Illinois at Chicago, Chicago, IL 60612, USA.; Jesse Brown VA Medical Center, Chicago, IL 60612, USA.; Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA., Heysek RV; Central Florida Cancer Institute, Davenport, FL 33837, USA., Vasily DB; Lehigh Valley Dermatology Associates, Ltd., Bethlehem, PA 18018, USA., Rowe R; RealSkin Dermatology, Waco, TX 76712, USA., McClure EM; University Hospitals Geauga Medical Center, Chardon, OH 44024, USA., O'Reilly K; Cape Henlopen Dermatology, P.A., Lewes, DE 19958, USA., Finkelstein SE; Center of Advanced Radiation Excellence (CARE) and Radiation Oncology Research, Associated Medical Professionals of NY, Syracuse, NY 13210, USA., Farberg AS; Bare Dermatology, Dallas, TX 75235, USA.; University of North Texas Health Science Center, Fort Worth, TX 76107, USA. |
| Abstrakt: |
Background/Objectives : Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) are non-melanoma skin cancers (NMSCs) and the most prevalent cancers in the United States. Image-guided superficial radiotherapy (IGSRT) is a relatively new treatment option that uses high-resolution dermal ultrasound integrated with superficial radiotherapy to improve tumor visualization. IGSRT is a clinically equivalent non-surgical alternative to Mohs micrographic surgery at 2 years of follow-up in early-stage NMSC, but larger cohort studies with longer follow-up periods that allow for analysis of patient outcomes by demographic and disease characteristics are needed. Methods : This large, retrospective cohort study was conducted to determine the effect of risk factors (tumor location, tumor stage, and sex) on 2-, 4-, and 6-year freedom from recurrence rates in 19,988 NMSC lesions treated with IGSRT, including lesions with complete treatment courses. Results : Overall freedom from recurrence rates were 99.68% at 2 years, 99.54% at 4 years, and 99.54% at 6 years; rates did not differ significantly by tumor location (head/neck versus other locations, p = 0.9) or sex (male versus female, p = 0.4). In contrast, there was a significant difference in freedom from recurrence rates when analyzed by tumor stage ( p = 0.004). Conclusions : There was no significant effect of tumor location or sex on freedom from recurrence in IGSRT-treated NMSC. Although there was a significant difference according to tumor stage, freedom from recurrence rates exceeded 99% at all stages. |
